Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in BioCryst Pharmaceuticals, Inc., Relay Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how BioCryst Pharmaceuticals, Inc., Relay Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About BioCryst Pharmaceuticals, Inc., Relay Therapeutics and Inc.

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Latest Biotechnology and BioCryst Pharmaceuticals, Inc., Relay Therapeutics, Inc. Stock News

As of April 27, 2026, BioCryst Pharmaceuticals, Inc. had a $2.2 billion market capitalization, compared to the Biotechnology median of $276.4 million. BioCryst Pharmaceuticals, Inc.’s stock is up 15.1% in 2026, up 4.6% in the previous five trading days and up 8.27% in the past year.

Currently, BioCryst Pharmaceuticals, Inc.’s price-earnings ratio is 7.4. BioCryst Pharmaceuticals, Inc.’s trailing 12-month revenue is $874.8 million with a 30.2% net profit margin. Year-over-year quarterly sales growth most recently was 209.2%. Analysts expect adjusted earnings to reach $0.474 per share for the current fiscal year. BioCryst Pharmaceuticals, Inc. does not currently pay a dividend.

As of April 27, 2026, Relay Therapeutics, Inc. had a $2.8 billion market cap, putting it in the 59th percentile of all stocks. Relay Therapeutics, Inc.’s stock is up 65.5% in 2026, down 16.6% in the previous five trading days and up 368.65% in the past year.

Currently, Relay Therapeutics, Inc. does not have a price-earnings ratio. Relay Therapeutics, Inc.’s trailing 12-month revenue is $15.4 million with a % net profit margin. As of April 27, 2026, Relay Therapeutics, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-1.515 per share for the current fiscal year. Relay Therapeutics, Inc. does not currently pay a dividend.

How We Compare BioCryst Pharmaceuticals, Inc., Relay Therapeutics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at BioCryst Pharmaceuticals, Inc., Relay Therapeutics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

BioCryst Pharmaceuticals, Inc., Relay Therapeutics and Inc.’s Quality Grades

Company	Ticker	Quality
BioCryst Pharmaceuticals, Inc.	BCRX	A
Relay Therapeutics, Inc.	RLAY	D

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

BioCryst Pharmaceuticals, Inc. has a Quality Score of 98, which is Very Strong. Relay Therapeutics, Inc. has a Quality Score of 36, which is Weak.

The Quality Grade Winner: BioCryst Pharmaceuticals, Inc.

As you can clearly see from the Quality Grade breakdown above, BioCryst Pharmaceuticals, Inc. has a better overall quality grade than Relay Therapeutics, Inc.. For investors who are looking for companies with higher quality than others in the same industry, BioCryst Pharmaceuticals, Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

BioCryst Pharmaceuticals, Inc., Relay Therapeutics and Inc.’s Momentum Grades

Company	Ticker	Momentum
BioCryst Pharmaceuticals, Inc.	BCRX	B
Relay Therapeutics, Inc.	RLAY	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

BioCryst Pharmaceuticals, Inc. has a Momentum Score of 66, which is Strong. Relay Therapeutics, Inc. has a Momentum Score of 98, which is Very Strong.

The Momentum Grade Winner: Relay Therapeutics, Inc.

As you can clearly see from the Momentum Grade breakdown above, Relay Therapeutics, Inc. is considered to have stronger momentum compared to BioCryst Pharmaceuticals, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Relay Therapeutics, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

BioCryst Pharmaceuticals, Inc., Relay Therapeutics and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
BioCryst Pharmaceuticals, Inc.	BCRX	C
Relay Therapeutics, Inc.	RLAY	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

BioCryst Pharmaceuticals, Inc. has a Earnings Estimate Score of 51, which is Neutral. Relay Therapeutics, Inc. has a Earnings Estimate Score of 59, which is Neutral.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither BioCryst Pharmaceuticals, Inc., Relay Therapeutics or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if BioCryst Pharmaceuticals, Inc., Relay Therapeutics or Inc. is the better investment when it comes to estimate revisions.

Other BioCryst Pharmaceuticals, Inc., Relay Therapeutics and Inc. Grades

In addition to Quality, Estimate Revisions and Momentum, A+ Investor also provides grades for Value and Growth.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether BioCryst Pharmaceuticals, Inc., Relay Therapeutics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, BioCryst Pharmaceuticals, Inc., Relay Therapeutics or Inc. Stock?

Overall, BioCryst Pharmaceuticals, Inc. stock has a Momentum Score of 66, Estimate Revisions Score of 51 and Quality Score of 98.

Relay Therapeutics, Inc. stock has a Momentum Score of 98, Estimate Revisions Score of 59 and Quality Score of 36.

Comparing BioCryst Pharmaceuticals, Inc., Relay Therapeutics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.